Shire has over 25 years experience and an established record in protein formulation and delivery development. He received his PhD in chemistry from Indiana University, and after his postdoctoral training at the University of Connecticut, he began his career at Genentech as Research Scientist in the Department of Protein Chemistry. He was involved in the early work to isolate heterologous recombinant proteins expressed in bacterial systems. This work led to the granting of a patent and served as the basis for further product development of proteins expressed in bacterial systems. During his tenure in the Protein Chemistry Department, he used numerous physicochemical techniques to characterize Genentech proteins at various stages of development.
Shortly after the creation of the Pharmaceutical Research and Development Department at Genentech, he joined the department where he made numerous contributions to the development of protein formulation and delivery. In addition, he set up one of the first analytical ultracentrifugation laboratories in the biotechnology industry. Currently, he is a Staff Scientist and Group Leader in the Late Stage Pharmaceutical and Device Development Department at Genentech, and an adjunct faculty member of the USC School of Pharmacy and University of Connecticut School of Pharmaceutical Sciences. He has been responsible for directing research and development of formulations for a variety of recombinant human proteins, including Pulmozyme® and Xolair®.
Shire has served as the chair of the American Association of Pharmaceutical Scientists' (AAPS) Biotechnology Section, and was elected as a Fellow of AAPS in 1998 and member-at-large to the AAPS Executive Council in 2001. He has published over 60 reviews and papers dealing with various aspects of formulation and pharmaceutical development of therapeutic proteins.